In 2022, a Chinese team published the results of a systematic review with meta-analysis of 76 clinical trials evaluating the risk of biliary disease in patients treated with incretin mimetic GLP-1 agonists: lira-glutide (Victoza°, Saxenda°), dulaglutide (Trulicity°), semaglutide (Ozempic°, Rybelsus°), exenatide (Byetta°, Bydure-on°), lixisenatide (Lyxumia°) or albiglutide (ex-Eperzan°). Most of the trials were carried out in diabetic patients and 13 in overweight patients (1).
展开▼
